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A single extracellular amino acid in 
Free Fatty Acid Receptor 2 defines 
antagonist species selectivity and  
G protein selection bias
Eugenia Sergeev1, Anders Højgaard Hansen2, Daniele Bolognini1, Kouki Kawakami3, Takayuki 
Kishi3, Junken Aoki3,4, Trond Ulven2, Asuka Inoue3,5, Brian D. Hudson1 & Graeme Milligan1
Free Fatty Acid Receptor 2 is a GPCR activated by short chain fatty acids produced in high levels in the 
lower gut by microbial fermentation of non-digestible carbohydrates. A major challenge in studying 
this receptor is that the mouse ortholog does not have significant affinity for antagonists that are able 
to block the human receptor. Docking of exemplar antagonists from two chemical series to homology 
models of both human and mouse Free Fatty Acid Receptor 2 suggested that a single lysine - arginine 
variation at the extracellular face of the receptor might provide the basis for antagonist selectivity 
and mutational swap studies confirmed this hypothesis. Extending these studies to agonist function 
indicated that although the lysine - arginine variation between human and mouse orthologs had 
limited effect on G protein-mediated signal transduction, removal of positive charge from this residue 
produced a signalling-biased variant of Free Fatty Acid Receptor 2 in which Gi-mediated signalling by 
both short chain fatty acids and synthetic agonists was maintained whilst there was marked loss of 
agonist potency for signalling via Gq/11 and G12/13 G proteins. A single residue at the extracellular face of 
the receptor thus plays key roles in both agonist and antagonist function.
The role of the microbiota in health and disease is currently attracting enormous interest1–3. Among a broad 
and diverse range of metabolites that the microbiota generate from ingested foodstuffs there has been particular 
focus on the production of short chain fatty acids (SCFAs) that are generated by fermentation of poorly digested 
carbohydrates and fiber in the lower gut4–6. Whilst SCFAs produced in this manner play wide-ranging roles, 
including acting as nutrients for colonocytes, the roles that they may play via activating a pair of cell surface G 
protein-coupled receptors (GPCRs) designated Free Fatty Acid receptor 2 (FFA2) and Free Fatty Acid receptor 3 
(FFA3)7,8 have attracted particular attention9–11. These receptors are expressed by a diverse set of enteroendocrine 
cells, immune cells, adipocytes and certain peripheral neurons. This expression profile suggests that the receptors 
might be potential therapeutic targets in disease areas that range from metabolic disorders to inflammatory con-
ditions of the lower gut8,10,12.
Previous studies showed that SCFAs produced by the microbiota centred in the colon activate FFA2 expressed 
in neutrophils and affect mucosal barrier function, resulting in inflammatory conditions of the lower gut, includ-
ing ulcerative colitis. Thus, FFA2 blockade has been considered as a potential therapeutic target to limit neutrophil 
infiltration and so alleviate such conditions. Indeed, the FFA2 antagonist 4-[[1-(benzo[b]thiophene-3-carbonyl)
-2-methylazetidine-2-carbonyl]-(3-chlorobenzyl)amino]butyric acid (GLPG0974) entered phase II clinical trials 
for treatment of ulcerative colitis but failed to show efficacy13. Further development of this ligand was therefore 
terminated. Nonetheless, both pre-clinical and clinical trials of GLPG0974 were able to show that this compound 
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was able to interact with FFA2 in human volunteers and patients, and effectively blocked chemotaxis of human 
neutrophils13,14. GLPG0974 is the only FFA2 ligand to date that has been employed in clinical studies and its lack 
of efficacy may indicate that a deeper understanding of the physiological functions of FFA2 is required to develop 
effective therapeutics. Limiting this desire are observations that GLPG0974 is highly selective for human (h)FFA2 
and is unable to effectively block rat or mouse orthologs of this receptor14,15. This clearly presents challenges to 
using GLPG0974 in both rodent-derived cell lines and tissues and in rodent models of disease. The molecular 
basis for the species ortholog selectivity of GLPG0974 and related molecules has not been defined. Exemplars 
from a second series of FFA2 antagonists also lack affinity at rodent orthologs of FFA216. A major aim of the 
current studies was thus to understand the molecular basis for these differences. Using combinations of ligand 
docking to receptor homology models and direct binding studies using a radiolabelled form of GLPG097415 as 
well as mutagenesis we show a key role of a single lysine to arginine variation at the extracellular face of human 
and mouse FFA2 in defining the ability of both antagonist classes to interact with high affinity with human but 
not mouse FFA2.
In the original studies that identified SCFAs as the endogenous activators of FFA2 the ability of this recep-
tor to signal through multiple classes of heterotrimeric G proteins was highlighted17. This is exemplified by the 
capacity of agonists to promote activation of both Gi-family G proteins, resulting in reduction in cellular levels of 
cAMP, and members of the Gq/11 family, that result in generation of inositol 1, 4, 5 trisphosphate and subsequent 
elevation of intracellular [Ca2+]. The concept of agonist ‘bias’ in promoting one signalling pathway over others 
has become well established in recent years18–20. In the case of FFA2 the agonist N-[3-(2-carbamimidamido-
4-methyl-1,3-thiazol-5-yl)phenyl]-4-fluoro benzamide (AZ1729) was recently shown to be markedly ‘biased’ in 
that although an effective and potent regulator of Gi-mediated signalling it is unable to promote signalling via 
Gq/11 family G proteins21. Although SCFAs and various synthetic FFA2 agonists can engage with both G protein 
classes via both human and mouse FFA222,23, removal of positive charge from the same residue position as defined 
to dictate antagonist binding selection between human and mouse FFA2 produced a form of the receptor in 
which agonist engagement with both Gq/11 and G12/13 signalling pathways was severely disrupted without hinder-
ing those mediated via Gi G proteins, generating a highly ‘biased’ form of the receptor. These outcomes illustrate 
the role of this single extracellular residue in defining both pharmacology and function of this receptor.
Results
A single Lysine-Arginine variation defines the human versus mouse selectivity of FFA2 antag-
onists. Following doxycyline-induced expression of hFFA2 in Flp-In TREx 293 cells the endogenous SCFA 
propionate (C3) and the synthetic FFA2 agonist 3-benzyl-4-(cyclopropyl-(4-(2,5-dichlorophenyl)thiazol-2-yl)
amino)-4-oxobutanoic acid (compound 1)23 were both able to promote accumulation of inositol monophosphates 
(Fig. 1a), with compound 1 being in the region of 1000 times more potent than C3 (Table 1). This effect was 
prevented by increasing concentrations of either of two exemplar hFFA2 antagonists, GLPG097414 and (S)-3-(2-
(3-chlorophenyl)acetamido)-4-(4-(trifluoromethyl)phenyl)butanoic acid (CATPB)22 (Fig. 1b), that derive from 
distinct chemical series (Fig. 1c)8. By contrast, when equivalent experiments were performed following expres-
sion of the mouse ortholog of FFA2 (mFFA2) C3-stimulated inositol monophosphate production was unaffected 
by either GLPG0974 or CATPB (Fig. 1b). Although structurally quite distinct (Fig. 1c), ligand docking studies 
using a homology model of hFFA2 previously indicated that the carboxylate moiety of each of these compounds 
interact, if differentially15, with a pair of arginines (residue numbers 180 and 255, positions 5.39 and 7.35, respec-
tively in the Ballesteros and Weinstein24 residue location system) that also interact with the carboxylate of both 
C3 and compound 1. Further analysis of the ligand docking studies also indicated the potential for a charge-as-
sisted hydrogen bond between one of the two amide-carbonyls of GLPG0974 and Lys65 of the receptor (Fig. 1di). 
Similarly, this also predicted Lys65 to participate in a charge-assisted hydrogen bond with the single amide-car-
bonyl of CATPB (Fig. 1dii). Overall, despite the structural differences between CATPB and GLPG0974 these 
interactions resulted in overlapping poses of the two antagonists (Fig. 1d insert).
Lys65 is located at the extracellular surface, at the very top of transmembrane domain II (position 2.60 in the 
nomenclature of Ballesteros and Weinstein24) of hFFA2. Although Lys65 lies outwith the previously identified 
core orthosteric agonist binding pocket of hFFA225 mutation of this residue to either Ala or to Glu resulted in a 
substantial loss of potency for both C3 and compound 1 in inositol monophosphate accumulation assays (Fig. 1e, 
Table 1). The modest potency of C3 at wild type hFFA2 and the limited solubility of compound 1 made assessment 
of the true extent of loss of potency at the Ala and Glu substitutions challenging to quantify accurately (Table 1) 
but in each case it was greater than 30 fold. By contrast, following mutation of Lys65 to Arg in hFFA2 only a small, 
but still statistically significant, reduction in potency of both C3 and compound 1 was observed (Fig. 1e, Table 1). 
Although the potency of the two tested agonist compounds was reduced substantially at both the Lys65Ala and 
Lys65Glu mutants of hFFA2, each mutant still responded at sufficiently high concentrations of compound 1 to 
allow assessment of the potential ability of GLPG0974 (Fig. 1f) and CATPB (Fig. 1g) to act as antagonists at 
these mutants. Both antagonists lost substantial potency at each of these two point mutants of hFFA2 (Table 1). 
Moreover, at Lys65Arg hFFA2 the ability of both GLPG0974 and CATPB to block compound 1-mediated elevation 
of inositol monophosphate accumulation was all but abolished (Fig. 1f,g). This was of particular interest because 
in mFFA2 residue65 is Arg rather than Lys. Docking of either GLPG0974 or CAPTPB to an equivalent homology 
model of mFFA2 resulted in poses for each ligand that were devoid of interactions with Arg65 (not shown) which, 
rather, was fixed in an ionic-lock conformation with residue Glu68 (Ballesteros and Weinstein residue position 
2.63). In concert with the functional data this was potentially consistent with the Lys65-Arg65 variation between 
hFFA2 and mFFA2 being responsible for the lack of function of both GLPG0974 and CATPB as antagonists at 
mFFA2 (Fig. 1b). To test this directly we generated the reverse mutation in which Arg65 in mFFA2 was converted 
to Lys. Gratifyingly, following expression of Arg65Lys mFFA2, both GLPG0974 and CATPB were able to fully 
antagonize C3-mediated inositol monophosphate accumulation, in a concentration-dependent manner (Fig. 1h).
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To extend these observations we performed sets of specific binding studies using the radioligand [3H]
GLPG097415. [3H]GLPG0974 bound with high affinity (Kd = 7.3 ± 0.4 nM) to hFFA2 (Fig. 2a). By contrast, no 
specific binding to Lys65Arg hFFA2 could be detected at up to 60 nM [3H]GLPG0974 (Fig. 2b). Moreover, in 
line with the reduced potency of GLPG0974 to inhibit agonist-induced inositol monophosphate accumulation 
Figure 1. Species selectivity of FFA2 antagonists for human versus mouse ortholog is determined by the 
identity of residue 65 in FFA2. Receptors of interest were expressed in-frame with eYFP in Flp-In TREx 293 
cells. (a) The ability of varying concentrations of C3 ( ) and compound 1 (●) to promote production of inositol 
monophosphates was assessed. (b) The capacity of varying concentrations of either GLPG0974 (●) or CATPB 
( ) to inhibit inositol monophosphate production induced by EC80 concentrations of C3 at either hFFA2 (●) or 
mFFA2 (○) was assessed. (c) Chemical structures of GLPG0974 and CATPB are shown. (d) Docking of 
GLPG0974 (di) and CATPB (dii) into a homology model of hFFA2 with focus on the potential interaction of 
each ligand with Lys65 (residue 2.60). The insert highlights overlapping poses of GLPG0974 (cyan) and CATPB 
(green) within the binding pocket despite their structural differences (e). The ability of varying concentrations of 
C3 ( ) and compound 1 (●) to promote generation of inositol monophosphates in Flp-In TREx 293 cells 
induced to express Lys65Arg (●), Lys65Ala (■), and Lys65Glu (▲) hFFA2 is illustrated. (f,g) The ability of 
GLPG0974 (f) or CATPB (g) to inhibit inositol monophosphate production induced by EC80 concentrations of 
compound 1 at wild type and each of Lys65Arg (○), Lys65Ala (□), and Lys65Glu (△) hFFA2 is shown. (h) The 
ability of GLPG0974 (●) or CATPB ( ) to inhibit inositol monophosphate production induced by C3 at wild 
type (dotted line) and Arg65Lys (●) mFFA2 is illustrated.
Compound WT K65R K65A K65E
C3 4.06 ± 0.08 3.71 ± 0.05* <2.5 <2.5
Compound 1 6.98 ± 0.06 6.70 ± 0.07* <5.5 <5.5
GLPG0974 7.92 ± 0.19 <4.5 7.36 ± 0.17 <4.5
CATPB 7.72 ± 0.14 <4.5 6.36 ± 0.19 <4.5
Table 1. Lys65Xaa alterations in hFFA2 affect both agonist potency to generate inositol monophosphates and 
the ability of antagonists to inhibit this response. Values represent pEC50 for agonists C3 and compound 1 and 
pIC50 values for antagonists GLPG0974 and CATPB against an EC80 concentration of compound 1. Data are 
mean ± SEM with n ≥ 3. *p ≤ 0.05. One-way analysis of variance was followed by Dunnett’s test with WT as 
reference.
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at Lys65Ala hFFA2 (Fig. 1f, Table 1), direct binding studies using [3H]GLPG0974 indicated that affinity of the 
radioligand at this mutant was reduced some 10 fold (Kd = 67 ± 9 nM) compared to wild type hFFA2 (Fig. 2c). 
Consistent with the functional inhibition produced by GLPG0974 at Arg65Lys mFFA2, direct binding studies 
with [3H]GLPG0974 showed the radioligand to bind with high affinity to this mutant of the mouse ortholog of 
FFA2 (Fig. 2d). However, as the measured affinity (Kd = 51 ± 11 nM) was some 7 fold lower than for wild type 
hFFA2, this single variation in sequence was unable to account fully for the human versus mouse FFA2 species 
differences in responsiveness to GLPG0974. Although loss of potency of both C3 and compound 1 was extensive 
at Lys65Ala hFFA2 when measured in inositol monophosphate accumulation assays (Table 1) the ability of each of 
these two agonists to bind to the Lys65Ala hFFA2 variant, as assessed by their ability to compete for binding with 
[3H]GLPG0974, was much less affected (Fig. 2e,f).
Removal of positive charge from residue 65 of Free Fatty Acid receptor 2 skews agonist-induced 
G protein selection. We next assessed the implications and potential basis of the apparent dichotomy 
between measured agonist binding affinity and functional potency in inositol monophosphate accumulation 
studies. Inositol monophosphate accumulation produced by agonists of FFA2 following expression of the recep-
tor in HEK293 cells reflects activation of Gq/11 heterotrimeric G proteins26. However, it is well established that 
FFA2 can also interact functionally with other heterotrimeric G proteins, including members of the pertussis 
toxin sensitive Gi-family17,21. We, therefore, also assessed agonist function at each of wild type hFFA2 and the set 
of Lys65-Xaa hFFA2 mutants described above in two distinct assays that each reflects activation of Gi-family G 
proteins. When measuring the ability of C3 to inhibit forskolin-amplified cAMP levels in intact cells expressing 
each variant the potency of the SCFA was unaffected (Lys65Glu), or only modestly reduced (Lys65Ala, Lys65Arg), 
compared to the wild type receptor (Fig. 3a, Table 2). For compound 1 this was even more marked with no signif-
icant reduction in potency noted at any of Lys65Glu, Lys65Arg or Lys65Ala hFFA2 (Fig. 3b, Table 2). However, for 
both the Lys65Glu and Lys65Ala hFFA2 mutants the maximal effect of both C3 and compound 1 was greater than at 
wild type hFFA2 (Fig. 3a,b). In [35S]GTPγS binding assays performed on membrane preparations of cells express-
ing these variants of hFFA2 this broad pattern was retained, with effects on potency of both C3 and compound 1 
limited to less than 6-fold (Fig. 3c and d, Table 2).
These modest changes in agonist potency in measures of Gi-mediated function compared to those observed in 
Gq/11-mediated inositol monophosphate accumulation studies suggested that mutation of Lys65 in hFFA2 might 
generate a ‘biased’ form of the receptor, in which effects mediated via Gq/G11 were altered more extensively than 
effects transduced via Gi-family G proteins. To test this hypothesis directly we first employed the FFA2 agonist 
AZ1729. We have previously shown that this ligand is able to transduce signals only via Gi-mediated pathways 
and not via Gq/G11 pathways21. As anticipated from this AZ1729 was unable to promote accumulation of inositol 
monophosphates via hFFA2 (Fig. 4a). By contrast AZ1729 both increased binding of [35S]GTPγS (Fig. 4a, Table 2) 
Figure 2. Binding of [3H]GLPG0974 to hFFA2 and various mutants. Total, nonspecific and specific (total 
minus nonspecific) binding of the indicated concentrations of [3H]GLPG0974 to membranes of Flp-In TREx 
293 cells induced to express wild type hFFA2 (a), Lys65Arg hFFA2 (b), Lys65Ala hFFA2 (c) or Arg65Lys mFFA2 
(d) is shown from representative experiments. The ability of C3 (e) and compound 1 (f) to compete with 
approximate Kd concentrations of [3H]GLPG0974 to bind to membranes expressing wild type (●) or Lys65Ala 
( ) hFFA2 is illustrated.
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and inhibited forskolin-stimulated levels of cAMP (Fig. 4a, Table 2) in a concentration-dependent manner. 
Alteration of Lys65 to Ala, Arg or Glu did not promote an ability of AZ1729 to stimulate inositol monophosphate 
accumulation (Fig. 4b) whilst, notably, the potency of AZ1729 in both of the Gi-coupled assays was completely 
unaffected by alteration of Lys65 to Ala, Arg or Glu (Fig. 4c and d, Table 2). This indicates that coupling of hFFA2 
to Gi-mediated end points is intrinsically unaffected by mutation of residue Lys65.
To examine potential shifts in G protein selection produced by mutation of Lys65 in hFFA2 more fully we 
next employed a transforming growth factor-α (TGFα) shedding assay27. Following transfection of wild type 
hFFA2 into parental HEK293 cells alongside a membrane-bound pro-form of alkaline phosphatase (AP)-tagged 
TGFα, addition of C3 resulted in shedding of AP-TGFα into the cell medium (Fig. 5a). This occurred in a 
concentration-dependent manner with pEC50 = 4.93 ± 0.04 (Table 3), notably some 10 fold higher than in the 
inositol monophosphate accumulation assay. The TGFα shedding assay integrates information on signal trans-
duction mediated via both Gq/11 and G12/13 G proteins27 and previous studies, in assays using Saccharomyces 
cerevisiae-based chimeric G proteins, have indicated that FFA2 can activate G12/13 as well as Gq/11 G proteins17. We, 
therefore, used the TGFα shedding assay system to investigate hFFA2 coupling to endogenous G12/13 G proteins 
and also to assess potential effects of mutation of Lys65 in hFFA2 on coupling of the receptor to members of this 
G protein subfamily. To resolve outcomes in the TGFα shedding assay that reflect coupling to Gq/11 from those 
Figure 3. Agonist responses in assays that reflect activation of Gi-G proteins are only modestly affected by 
charge-modifying mutations of Lys65 in hFFA2. The ability of C3 (a,c) and compound 1 (b,d) to promote 
inhibition of forskolin-amplified cAMP levels (a,b) or to enhance binding of [35S]GTPγS (c,d) at each of wild 
type hFFA2 (●), Lys65Arg hFFA2 (○), Lys65Ala hFFA2 (□) or Lys65Glu (△) hFFA2 is illustrated.
Assay Agonist WT K65R K65A K65E
cAMP
C3 3.90 ± 0.09 3.42 ± 0.06** 3.20 ± 0.11*** 3.79 ± 0.08
Compound 1 6.37 ± 0.06 6.18 ± 0.08 6.54 ± 0.10 6.47 ± 0.13
AZ1729 6.35 ± 0.13 6.47 ± 0.15 6.42 ± 0.03 6.45 ± 0.15
GTPγS
C3 3.59 ± 0.08 3.29 ± 0.08* 2.83 ± 0.06*** 3.21 ± 0.05**
Compound 1 6.46 ± 0.04 6.52 ± 0.06 5.68 ± 0.08*** 5.98 ± 0.07***
AZ1729 6.97 ± 0.02 6.79 ± 0.07 6.94 ± 0.14 6.79 ± 0.12
Expression (% of WT) 100 ± 1 187 ± 3 96 ± 1 97 ± 1
Table 2. Lys65Xaa alterations in hFFA2 have limited effects in assays that are transduced via Gi-G proteins. 
Values represent pEC50 of agonists in respective assays. Data are mean ± SEM with n ≥ 3. *p ≤ 0.05. **p ≤ 0.01. 
***p ≤ 0.001. One-way analysis of variance was followed by Dunnett’s test with WT as reference.
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that reflect coupling to G12/13 the TGFα shedding assays were performed in HEK293 cells genetically modified by 
CRISPR/Cas9 genome editing. These cell lines either lacked expression of both Gαq and Gα1126,28, and therefore 
signals are limited to those generated via G12 and/or G13, or lacked expression of both G12 and G1329 and, there-
fore, generate signals only via Gq and/or G11. In each of these genome-edited cell lines shedding of TGFα was also 
promoted by C3 in a concentration-dependent manner (Fig. 5a), although in both these cases the potency of C3 
was lower than in equivalent assays performed in parental HEK293 cells (Table 3). Consistent with the concept 
that the TGFα shedding assay reflects only activation of these specific G protein subgroups, when similar assays 
were performed in HEK293 cells in which expression of all four of these G protein α subunits (Gαq, Gα11, Gα12, 
Gα13) had been eliminated30, no TGFα shedding response to C3 was produced (Fig. 5a). To assess the signalling 
profile of hFFA2 in further detail, the HEK293 cells genome-edited to lack all four of the Gα subtypes that can 
induce the TGFα shedding response were employed and transfected individually with each of Gαq, Gα11, Gα12 
and Gα13, alongside wild type hFFA2. Each of the four specific G protein α subunits (Gαq, Gα11, Gα12, Gα13) was 
able to reconstitute C3-mediated function (Fig. 5b). However, the signal produced in the presence of Gαq or Gα11 
was substantially greater than for Gα13 and, particularly, for Gα12 (Fig. 5b). It was uncertain from these data if the 
poor response in the presence of Gα12 and, to a lesser extent, Gα13 reflected weak coupling of these G proteins 
to hFFA2 compared to Gαq and Gα11 or poor downstream coupling to the mechanisms of induced TGFα shed-
ding. To define this we employed chimeric G proteins consisting of the backbone of Gαq with substitution of the 
C-terminal six amino acids of Gαq with the corresponding sequence from Gα12 or Gα13 because this region of the 
G protein C-terminal α5 helix defines receptor-G protein selection31. Now, introduction of AP-tagged TGFα and 
hFFA2 alongside Gαq−13 and Gαq−12 chimeric G proteins resulted in substantially more robust shedding of TGFα 
induced by C3 than observed when using full length Gα12 or Gα13 (Fig. 5c). This suggests that Gα12 in particular 
interacts poorly with the mechanisms that induce TGFα shedding but this G protein does couple effectively to 
hFFA2. Equivalent outcomes were produced when using compound 1 as agonist rather than C3 in each of these 
assay formats (Fig. 5d–f). As for C3, the potency of compound 1 in the TGFα shedding assay performed in paren-
tal HEK293 cells was also some 10 fold higher than in the inositol monophosphate studies (compare Table 3 and 
Table 1).
Given that the genome-edited HEK293 cell lines allowed separate assessment of coupling of hFFA2 to the Gq/11 
and G12/13 G protein subfamilies, we next assessed whether mutation of Lys65 in hFFA2 also differentially ‘biased’ 
coupling between these G protein subsets. It did not: In each of G12/13-deleted and Gq/11-deleted HEK293 cell lines 
Lys65Arg hFFA2 had no, or very limited, effect on the potency and function of either C3 or compound 1 (Fig. 6, 
Figure 4. Signalling of AZ1729 is unaffected by mutation of Lys65 in hFFA2. The ability of varying 
concentrations of AZ1729 to regulated cAMP levels ( ), promote binding of [35S]GTPγS ( ) and promote 
production of inositol monophosphates (●) in cells or membranes induced to express hFFA2 is illustrated (a). 
(b) AZ1729 is unable to promote inositol monophosphate production via Lys65Arg hFFA2 (○), Lys65Ala hFFA2 
(□) or Lys65Glu (△) hFFA2. (c,d) Potency of AZ1729 is unaffected at Lys65Arg hFFA2 (○), Lys65Ala hFFA2 (□) or 
Lys65Glu (△) hFFA2 in [35S]GTPγS (c) or cAMP inhibition (d) studies.
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Table 3). By contrast, for both Lys65Ala hFFA2 and Lys65Glu hFFA2 large, and similar, reductions in potency for 
both agonists was observed (Fig. 6, Table 3).
Usefully, the noted higher potency of both agonist ligands at wild type hFFA2 in this assay compared to the 
inositol monophosphate studies resulted in improved data quality and measurement of the extent of loss of ago-
nist potency at Lys65Ala hFFA2 and Lys65Glu hFFA2 (Fig. 6, Table 3). This allowed efficient calculation of the 
degree of ‘bias’ between Gi and Gq/G11 and G12/G13 signalling imbued by alteration of Lys65 to either Ala or Glu in 
hFFA2 (Table 4). These showed that for the endogenously generated SCFA C3, alteration of Lys65 to either Ala or 
Glu resulted in receptor function that was biased between 41–60 fold to favor Gi-mediated signalling compared 
to wild type hFFA2 when calculations were based on the data from [35S]GTPγS binding studies, and between 
100–125 fold when using data from cAMP inhibition studies (Table 4). Equivalent calculations based on the func-
tion of compound 1 resulted in assessed bias towards Gi-mediated pathways being less extensive, but still between 
21–27 fold when using values derived from cAMP inhibition studies (Table 4).
Discussion
Although in general not well characterized, there are a number of examples in which synthetic, small molecule, 
pharmacological tool compounds display marked variation in interactions with species orthologs of members 
of the G protein-coupled receptor superfamily. As initial screens for function invariably use the human receptor 
ortholog expressed in heterologous cell systems, this can create major challenges for understanding the basic 
underpinning biological roles of a receptor in animal models, as such efforts frequently centre on rodents and 
Figure 5. Activation of hFFA2 by C3 and by compound 1 induces TGFα shedding via both Gq/11 and G12/13 
(a,d) Varying concentrations of C3 (a) or compound 1 (d) were able to promote shedding of TGFα via hFFA2 
in each parental HEK293 cells and those genome edited to lack (Δ) expression of Gq+G11, or G12+G13 but not 
in cells genome edited to lack all four of these G protein α subunits (ΔΔ). (b,e) Reintroduction of each of Gαq, 
Gα11, Gα12 and Gα13 into cells lacking all four of these G proteins allowed reconstitution of TGFα shedding via 
FFA2 by both C3 (b) and compound 1 (e). (c,f) Introduction of chimeric Gαq−12 or Gαq−13 into HEK293 cells 
genome edited to lack each of Gαq, Gα11, Gα12 and Gα13 resulted in effective shedding of TGFα in response to 
C3 (c) and compound 1 (f).
Cells Agonist WT K65R K65A K65E
Parental
C3 4.93 ± 0.04 4.68 ± 0.09 2.23 ± 0.13*** 2.79 ± 0.07***
Compound 1 8.12 ± 0.08 8.14 ± 0.03 6.88 ± 0.04*** 6.88 ± 0.04***
ΔGq/11
C3 4.40 ± 0.07aaa 3.98 ± 0.04* 2.67 ± 0.17*** 2.39 ± 0.07***
Compound 1 7.84 ± 0.08a 7.51 ± 0.10 6.02 ± 0.11*** 5.94 ± 0.08***
ΔG12/13
C3 4.38 ± 0.10aaa 4.11 ± 0.09 2.14 ± 0.08*** 2.52 ± 0.05***
Compound 1 7.49 ± 0.08aaa 7.33 ± 0.11 6.23 ± 0.11*** 6.16 ± 0.13***
Table 3. Potency of FFA2 agonists in the TGFα shedding assay and effects of Lys65Xaa mutations. Values 
represent pEC50 of agonists in denoted cell lines. Data are mean ± SEM with n ≥ 3. */ap ≤ 0.05. **/aap ≤ 0.01.  
***/aaap ≤ 0.001. One-way analysis of variance was followed by Dunnett’s test with WT (*) or parental cells (a) as 
reference.
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tissue derived from this group of animals. An example is that all currently described antagonists of FFA2, whilst 
displaying moderately high affinity at the human ortholog are not able to effectively block mouse or rat FFA29,16. 
Although atomic level structures of FFA2 are not available, structures of the related free fatty acid receptor 1 
Figure 6. Removal of positive charge from residue65 in hFFA2 affects response to agonists in Gq/11- and G12/13-
coupled TGFα shedding assays in a manner akin to inositol monophosphate assays. TGFα shedding assays were 
performed in response to varying concentrations of C3 (a,c,e,g) or compound 1 (b,d,f,h) in parental HEK293 
cells (a,b), or those genome-edited to lack both Gαq and Gα11 (c,d), both Gα12 and Gα13, (e,f) or each of Gαq, 
Gα11, Gα12 and Gα13 (g,h) and transfected to express either wild type hFFA2 (dotted lines) or Lys65Arg hFFA2 
(○), Lys65Ala hFFA2 (□) or Lys65Glu (△) hFFA2.
www.nature.com/scientificreports/
9SCIenTIfIC REpoRTS | 7: 13741  | DOI:10.1038/s41598-017-14096-3
(FFA1) have been published32,33. We, therefore, initially developed homology models of both human and mouse 
FFA2 and attempted to dock the most widely studied exemplars, GLPG0974 and CATPB, of the two currently 
available antagonist series16 into each. These studies confirmed previously identified interactions of the carbox-
ylate group present in both antagonist molecules with the pair of arginine residues located at positions 5.39 
and 7.35 in hFFA2, as well as the relative preference for interaction of GLPG0974 with arginine 5.39 and of 
CATPB with arginine 7.3515. However, replacement of the carboxylate of both CATPB, and of an antagonist 
closely related to GLPG0974 with a methyl ester has been shown to result in only relatively modest reductions in 
ligand affinity15. This implies important roles for other residues in hFFA2 in recognition and binding affinity of 
CATPB and GLPG0974. For both, further interactions were highlighted herein in ligand docking studies using 
the homology model of hFFA2. The benzothiophene moiety of GLPG0974, a group that is critical for binding 
of GLPG0974-type compounds containing 3-chlorophenyl14, was sandwiched between Phe89 (residue location 
3.28) (π-stacking interaction) and Lys65 (residue location 2.60) (π–cation interaction) (Fig. 1di). Lys65 also was 
able to form a charge-assisted hydrogen bond to one of the amide carbonyls of GLPG0974 (Fig. 1di), locking the 
compound in place within the binding site. For CATPB, Lys65 of hFFA2 was also able to form a charge-assisted 
hydrogen bond to the single amide carbonyl (Fig. 1dii). Moreover, this residue also generated a π–cation inter-
action with the 3-chlorophenyl group of the antagonist (Fig. 1dii). Furthermore, the trifluoromethylphenyl of 
CATPB engaged Phe89 through π-stacking interactions (Fig. 1dii).
To consider why CATPB and GLPG0974 and related molecules do not act as effective antagonists at mouse 
FFA2, we also compared sequence alignments. Although Phe89 and residues in close proximity within the primary 
sequence of human and mouse FFA2 are fully conserved (Fig. 7), the Lys65 residue in human FFA2 is replaced by 
Arg in mouse (Fig. 7). We were unable to obtain docking poses in which interactions with Arg65 were detected for 
either CATPB or GLPG0974 using a homology model of mFFA2. However, in silico substitution of Lys for Arg65 in 
this model resulted in a pose for CATPB that was indistinguishable from those obtained with the hFFA2 homol-
ogy model (Fig. 8a). Whilst docking poses for GLPG0974 using Lys65Arg mFFA2 were distinct from those using 
wild type hFFA2 (Fig. 8b), GLPG0974 did, however, display important interactions with both Lys65 and Arg180 in 
this model (Fig. 8b). This may be why in studies using [3H]GLPG0974, although we observed each of high affinity 
binding of this ligand to wild type hFFA2, that such high affinity binding was eliminated by replacement of Lys65 
by Arg and high affinity binding of [3H]GLPG0974 to wild type mFFA2 was lacking. Binding affinity generated 
by the reverse alteration, in which the Arg found in this position in mFFA2 was replaced by Lys, was some 7 fold 
lower than to wild type hFFA2.
Pathway 1 Pathway 2 Agonist
β factor (compared to WT)
K65R K65A K65E
cAMP TGFα shedding
C3 −0.30 2.00 2.10
Compound 1 −0.39 1.44 1.33
GTPγS TGFα shedding
C3 −0.10 1.78 1.62
Compound 1 −0.03 0.36 0.59
Table 4. Agonist ‘bias’ factors for Lys65Xaa alterations in hFFA2.
Figure 7. Sequence alignment of FFA2 orthologs. Clustal Omega alignments of the primary amino acid 
sequence of available orthologs of FFA2 using human residues 60 to 119 as reference. Whether Lys or Arg 
is present as residue 65 (location 2.60) is shown in color. Glu68 (location 2.63) is fully conserved and Phe89 
(location 3.28) is also entirely conserved apart from in kangaroo rat, western clawed frog and channel catfish.
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To consider broader implications and to predict whether GLPG0974 would bind with high affinity to FFA2 
orthologs from other species we searched more widely across available sequence data. This indicated that each 
of rat, hamster and guinea-pig FFA2 also has Arg at position 65 and, therefore, would not be predicted to bind 
GLPG0974 with significant affinity (Fig. 7). This variation seems to be largely restricted to rodents. One rodent 
that does not follow this pattern is kangaroo rat, which has Lys at this position and, as such, we predict that 
GLPG0974 would have high affinity at FFA2 in this species, although the replacement of Phe89 by Gln may con-
found this prediction. Moreover, from the modelling/ligand docking and functional studies we predict that antag-
onists related to CATPB will also show the same pattern of species selectivity. Given this analysis, it is clear why14 
and13 were unable to explore the potential effectiveness of GLPG0974 in rodent models of disease and were forced 
to move directly to first-in-man clinical trials using this molecule without doing so. Clearly, a potential means to 
overcome this would be to generate lines of ‘humanized’ knock-in mice in which either the coding sequence of 
FFA2 was altered to the human form, or a single Arg65Lys alteration was introduced into the mFFA2 sequence. 
It is likely, however, that considering only Lys versus Arg identity at residue 65 in FFA2 as a predictor of high 
binding affinity for CATPB, GLPG0974 and related ligands will be too simplistic to explain this variation more 
broadly between species. For example, bovine FFA2 has Lys at residue 65 but does not bind CAPTB with high 
affinity (Hudson et al., unpublished). However, the loss and gain of function when switching these amino acids 
between primate and rodent orthologs of FFA2 is sufficient to provide important new insights into antagonist 
pharmacology at this receptor and may allow the synthesis of antagonists that have high affinity at wild type 
rodent orthologs of FFA2.
Interestingly, this is not the only study in which a Lys65 Arg mutation of hFFA2 has been employed. As con-
firmed herein Grundmann et al.34 showed that the agonist function of C3 was unaffected by this mutation, which 
will be discussed in more detail below. However, unlike the current studies in which both of the human specific 
antagonists GLPG0974 and CATPB lost substantial affinity at Lys65Arg hFFA2, Grundmann et al.34 reported 
CATPB to be an effective and competitive antagonist of C3 at this mutant. Although GLPG0974 was not assessed 
by Grundmann et al.34, their observations on the effectiveness of CATPB at this mutant are not compatible with 
either the current results, nor the inability of this compound to block rodent orthologs of FFA2, a feature that 
is well established8,16. Moreover, data shown here demonstrates across a range of assays that the ‘humanising’ 
Arg65Lys alteration in mFFA2 results in a gain of antagonist function, which confirms that antagonist species 
selectivity is indeed defined by the identity of the residue in position 65.
Sequence variation and alteration in ligand function between species orthologs of FFA2 is not restricted 
to antagonist pharmacology. In initial studies on Lys65Arg hFFA2 only modest variation was observed for the 
potency of either the endogenous agonist C3 or the synthetic FFA2 agonist compound 1. This is consistent with 
earlier studies that indicated, across a range of assays, whilst C3 is more potent at hFFA2 than at mFFA2, this 
difference is only in the region of three-fold22,23. Notably in this regard, Lys65Arg hFFA2 also showed some 2–3 
fold reduction in potency for C3 compared to wild type hFFA2. The synthetic agonist compound 1 has also been 
described as being slightly more potent at hFFA2 compared to either mFFA2 or the rat ortholog23 and, again, such 
reduction in potency was also observed at Lys65Arg hFFA2 compared to the wild type receptor. More extensive 
effects on both agonists were observed, however, when the positive charge at residue 65 was either eliminated or 
converted to a negative charge. However, the degree of effect was markedly dependent upon the assay employed 
and which G protein-mediated signalling pathway was being assessed.
Figure 8. Predicted mode of binding of antagonists to Arg65Lys mouse FFA2. Docking of CATPB (a) and 
GLG0974 (b) into a homology model of mouse FFA2 containing an Arg65Lys alteration. (a) Docking position 
of CATPB to human FFA2 (green) is overlaid with the low energy pose obtained for CATPB in Arg65Lys mouse 
FFA2 (yellow). Insert to A illustrates that in the model of wild type mouse FFA2 the position of Arg65 is fixed via 
an ionic interaction with Glu68 (residue 2.63). (b) Illustration of binding of GLPG0974 to Arg65Lys mouse FFA2 
and the importance of Lys at position 65.
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Although GPCRs are often classified as Gs, Gi or Gq-coupled, based on the predominant family of 
hetero-trimeric G proteins they interact with and activate to transduce intracellular signalling, this is routinely 
an oversimplification. This reflects that many receptors are appreciated to have the ability, as least when expressed 
in heterologous systems, to couple to members of more than one of the four broad subgroups of mammalian G 
proteins. Moreover, because the Gs, Gi or Gq-coupling preference of individual receptors is based most often on 
outcomes from assays that measure changes in amounts of intracellular 2nd messengers, such classifications rou-
tinely ignore contributions of the G12/13-family G proteins as these interactions are more challenging to measure 
because they do not directly modulate 2nd messenger levels. Contributions of Gs, Gi or Gq-family G proteins to 
the totality of canonical, G protein-mediated signalling can also be mapped via the use of bacterial toxins that 
modify various G protein α subunits31 and, more recently, small molecule inhibitors of the Gq/11 group of G pro-
teins26. However, only with the recent development of lines of HEK293 cells that have been genome-edited using 
CRISPR/Cas 9 technology28–30 has it been possible to explore the effect of re-introduction of individual G protein 
α subunits in engineered G protein-null backgrounds. Initial studies highlighted that although removal of posi-
tive charge from residue 65 of hFFA2 had, at most, modest effects on agonist potency at signalling endpoints that 
reflected activation of pertussis toxin-sensitive Gi-family G proteins, in inositol monophosphate accumulation 
assays that reflect activation of Gq/11 G proteins, much larger effects were recorded. This immediately suggested 
that elimination of positive charge at this residue generated a ‘biased’ form of the receptor at which signalling via 
Gi was preferred over signalling to Gq/11 or to G12/13. In recent times ligand or receptor signalling ‘bias’ has fre-
quently been taken to reflect differences in the ability of distinct ligands to harness interactions with a G protein 
compared to a non-canonical receptor interacting protein, most frequently an arrestin18. However, ligands that 
result in distinct patterns of receptor engagement with G protein subtypes compared to those produced by the 
(a) endogenous agonist clearly also ‘bias’ function of the receptor and this may have physiological consequences 
at least as important as altering selection between G protein and non-G protein-dependent signalling. Recent 
informatics studies have tried to understand and predict G protein selection by receptors35,36.
To potentially confirm and extend this hypothesis we employed a TGFα shedding assay that reports on acti-
vation of combinations of Gq/11 and G12/13 family G proteins to probe the G protein selection profile of FFA2. As 
well as confirming the ability of orthosteric agonists to engage with members of each of the Gi, Gq/11 and G12/13 
G protein groups these assays provided confirmation of the ‘biased’ nature of forms of hFFA2 lacking a positive 
charge at residue 65. Calculation of the extent of bias to favour signalling via Gi at these receptor variants was 
similar whether positive charge was simply removed or replaced with fixed negative change and was most exten-
sive, in the region of 100 fold, for the endogenous agonist C3. This has considerable implications for function. 
Sequence alignments failed to identify any species in which a positively charged residue, either Lys or Arg, is not 
located at this position. However, once again it would be possible to generate transgenic knock-in mice in which 
Gq/11-mediated signalling is predicted to be severely compromised compared to Gi-mediated signalling. As we 
have shown previously21 although the role of FFA2 as an anti-lipolytic regulator in white adipocytes is trans-
duced via Gi, FFA2-mediated control of GLP-1 release from enteroendocrine cells is a Gq/11-mediated process. As 
such, in mice expressing Arg65Ala or Arg65Glu mFFA2 (or indeed Lys65Ala or Lys65Glu hFFA2) we would predict 
that whilst C3-mediated regulation of lipolysis would be unaffected, SCFA-mediated regulation of GLP-1 release 
would be all but attenuated. Future studies will assess these hypotheses.
Methods
Materials. FFA2 ligands compound 123 and AZ172921 were synthesized as described previously. [3H]
GLPG0974 (129 MBq/mL) was a gift of AstraZeneca (Molndal, Sweden). [35S]GTPγS was from PerkinElmer Life 
Sciences. Tissue culture reagents were from Invitrogen and molecular biology enzymes and reagents from New 
England BioLabs. All other experimental reagents were from Sigma-Aldrich unless indicated otherwise.
Plasmids and mutagenesis. Human wild type and mutant FFA2 receptors with NanoLuc Luciferase fused 
to their N terminus were cloned into the pcDNA5/FRT/TO expression vector as described previously37 and used 
to generate doxycyline-inducible Flp-In T-REx HEK293 cell lines. For assays based on transient transfection 
a pcDNA5/FRT/TO vector expressing receptors fused to an HA-tag at their C terminus was cloned as previ-
ously described38. Site-directed mutagenesis to generate the point mutants of FFA2 was performed according 
to the QuikChange method (Stratagene, Cheshire, UK). The identity of all constructs was verified by nucleotide 
sequencing.
Cell culture, transfection and generation of cell lines. HEK293 cells were used for experiments 
employing transient heterologous expression of receptors of interest. These cells were maintained in Dulbecco’s 
Modification of Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1 x 
penicillin/streptomycin mixture (Sigma-Aldrich) at 37 °C with 5% CO2. Transfections were performed using pol-
yethyleneimine and experiments carried out 48 h post-transfection. In experiments utilizing HEK293 cells with 
doxycycline-inducible stable receptor expression, the Flp-In T-REx system (Invitrogen) was used for cell line gen-
eration as described previously39. Medium for Flp-In T-REx HEK293 cells was additionally supplemented with 
5 μg/ml blasticidin and 200 μg/ml hygromycin B. All experiments carried out using these cells were conducted 
after a 24 h treatment with 100 ng/ml doxycycline to induce expression of the receptor construct of interest.
HTRF-based cAMP inhibition and inositol monophosphate accumulation assays. All cAMP 
and inositol monophosphate experiments were performed using Flp-In T-REx HEK293 cells induced to express 
the receptor of interest. Experiments were carried out using respective homogenous time-resolved FRET-based 
detection kits (CisBio Bioassays; CisBio, Codolet, France) according to the manufacturer’s protocol. For the 
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cAMP inhibition assay cells were plated at 2000 cells/well in low-volume 384-well plates. The ability of agonists 
to inhibit 1 μM forskolin-induced cAMP production was assessed following a co-incubation for 30 min with 
agonist compounds. For the inositol monophosphate accumulation assay cells were plated at 7500 cells/well in 
low-volume 384-well plates and incubated for 2 h at 37 °C with test compounds. To assess ability of antagonists 
to inhibit agonist responses, cells were pre-incubated with antagonist compounds for 30 min at 37 °C prior to 
addition of an EC80 concentration of agonist. Respective reactions were stopped according to the manufacturer’s 
instructions and the output was measured by with a PHERAstar FS plate reader (BMGLabtech, Aylesbury, UK).
Membrane preparation. Membranes were generated from Flp-In T-REx HEK293 cells treated with 100 ng/
mL doxycycline to induce expression of receptor of interest. Cells were washed with ice-cold phosphate-buffered 
saline, removed from dishes by scraping and centrifuged at 3000 rpm for 5 min at 4 °C. Pellets were resuspended 
in TE buffer (75 mM Tris-HCl, 5 mM EDTA; pH 7.5) containing a protease inhibitor mixture (Roche Applied 
Science, West Sussex, UK) and homogenized with a 5 ml hand-held homogenizer. This material was centrifuged 
at 1500 rpm for 5 min at 4 °C and the supernatant was further centrifuged at 50000 rpm for 30 min at 4 °C. The 
resulting pellet was resuspended in TE buffer and protein content was assessed using a BCA protein assay kit 
(Pierce, Fisher Scientific, Loughborough, UK).
[35S]GTPγS incorporation assay. Initially, 5 μg of generated membrane protein was pre-incubated for 
15 min at 25 °C in assay buffer (50 mM Tris-HCl, 10 mM MgCl2; 100 mM NaCl; 1 mM EDTA; 1 μM GDP; 0.1% 
fatty acid-free bovine serum albumin; pH 7.4) containing the indicated ligand concentrations. The reaction was 
then initiated with addition of [35S]GTPγS at 50 nCi per tube, and the reaction was terminated after 1 h incuba-
tion at 25 °C by rapid filtration through GF/C glass filters using a 24-well Brandel cell harvester (Alpha Biotech, 
Glasgow, UK). Unbound radioligand was removed from filters by three washes with ice-cold wash buffer (50 mM 
Tris-HCl, 10 mM MgCl2; pH 7.4) and filters were dried for 2–3 h at room temperature. Dried filters were added 
to 3 mL of Ultima GoldTM XR (PerkinElmer Life Sciences, Beaconsfield, UK) and [35S]GTPγS binding was deter-
mined by liquid scintillation spectrometry.
Radioligand binding assay. Assays were carried out either with increasing concentrations (for saturation 
binding) or respective Kd concentrations (for displacement assays) of [3H]GLPG097415, binding buffer (50 mM 
Tris-HCl, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA; pH 7.4), and the indicated concentrations of test com-
pounds (for displacement assays) in a total assay volume of 200 µl in glass tubes. Binding was initiated by the 
addition of membranes (5 µg of protein per tube). All assays were performed at 25 °C for 2 h before termination 
by the addition of ice-cold phosphate-buffered saline and vacuum filtration through GF/C glass filters using a 
24-well Brandel cell harvester (Alpha Biotech, Glasgow, UK). Each reaction well was washed three times with 
2 ml of binding buffer. The filters were allowed to dry for 2–3 h and then placed in 3 ml of Ultima GoldTM XR. 
Radioactivity was quantified by liquid scintillation spectrometry. Specific binding was defined as the difference 
between binding detected in the presence and absence of 10 µM unlabeled GLPG0974.
TGFα shedding assay. A mixture of 250 ng AP-TGFα, 100 ng receptor of interest and 50 ng Gα protein 
were transfected using polyethyleneimine into one well of HEK293 cells cultured in a 12-well plate. Transfected 
cells were detached with PBS containing 0.05% trypsin and 0.52 mM EDTA and harvested by centrifugation at 
190 × g for 5 min. The cell pellet was resuspended in PBS, followed by an incubation for 15 min at room temper-
ature. After a second centrifugation at 190 × g for 5 min, pelleted cells were resuspended in 4 ml Hank’s Balanced 
Salt Solution (HBSS) containing 5 mM HEPES (pH7.4) per well in a 12-well plate. The cell suspensions were 
plated at 90 μl per well in a 96-well plate and incubated at 37 °C with 5% CO2 for 30 minutes. After the equilibra-
tion period 10 μl per well of 10× concentration of compounds were added and incubated for 1 h at 37 °C with 5% 
CO2. Plates were centrifuged at 190 × g for 2 min and 80 μL of supernatant was transferred into another 96-well 
plate. Solution containing p-NPP (10 mM p-NPP, 40 mM Tris-HCl (pH 9.5), 40 mM NaCl, 10 mM MgCl2) was 
added at 80 μl per well into supernatant-only plates as well as cell plates. Absorbance at 405 nm of both plates 
was read before and after a 2 h incubation at room temperature using a microplate reader (VersaMax, Molecular 
Devices). Detailed assay development and analysis has been described previously27.
Homology modeling. Homology models of FFA2 receptors were constructed using the hFFA1 receptor 
(Protein Data Bank code 4PHU) as template32. The template was prepared for homology modeling as described 
previously15. The total sequence identity between FFA1 and FFA2 was determined to be 26%. The sequence iden-
tity between the transmembrane domains and hFFA2 and hFFA1 is 32%40. Key anchoring residue reported in 
this study (Lys65) and previously (Arg180, His242, Arg255)15 are all situated within the transmembrane domains of 
FFA2. Models of hFFA2, mFFA2, and Arg65Lys mFFA2 were generated using Prime’s homology modeling mod-
ule (Prime, version 3.3, Schrödinger, LLC, New York). For mFFA2, Arg65 and Glu68 were manually paired up in 
an ionic lock, and all final models underwent restrained minimization using OPLS-2005 force field in Protein 
Preparation Wizard41.
Ligand preparation and induced fit docking. Ligands (GLPG0974 and CATPB) were primed for 
docking using the OPLS-2005 force field in LigPrep (LigPrep, version 2.7, Schrödinger, LLC); ionization states 
were computed using Epik at pH 7.0 ± 2.0 (Epik, version 2.5, Schrödinger, LLC). Induced fit docking was exe-
cuted for both antagonists using the IFD 2006 protocol (Glide version 5.9, Schrödinger, LLC; Prime version 
3.2, Schrödinger, LLC). For hFFA2 the centroid of the binding site, into which GLPG0974 and CATPB were 
docked, was defined by residues: 14, 58, 61–69, 89, 90, 165, 166, 176, 179–181, 184, 242. Within hFFA2, residues 
≤3 Å from each docked ligand were used to define the centroid of binding sites for mFFA2 and mFFA2-R65K. 
For all cases, trimming was executed for residues 89, 90, 165, 87, 145, 141, 179, while residues 65 and 255 were 
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not refined during induced fit docking. Sampling of ligand conformations was performed using default settings; 
docking of ligands was executed using Glide Extra Precision (XP)42; a maximum number of 20 poses per ligand 
was allowed, and re-docking was executed in Glide XP mode for structures within 30 kcal/mol of the lowest 
energy protein-ligand complex. Residues refinement was set to ≤5 Å of each ligand pose. Poses were selected 
based on three criteria. First, and due to the key role of Lys65 in ligand binding and ortholog specificity, only 
docked ligands that actively engaged Lys65 were analyzed. Second, as a reference, our previous study on FFA2 
antagonist binding15 was used as a guideline to how the carboxylate of docked ligands was oriented towards the 
key arginine residues (Arg180, Arg255). Third, to disregard unrealistic poses of compounds with high ligand strain, 
only the lowest energy poses fulfilling the aforementioned criteria were considered.
Data analysis. All data are presented as means ± SEM of at least three independent experiments. Data anal-
ysis and curve fitting was carried out using the GraphPad Prism software package version 5.0b (GraphPad, San 
Diego). For functional assays the concentration-response data were plotted on a log axis, with the untreated 
vehicle control plotted at 1 log unit lower than the lowest ligand concentration, and fitted to a three parameter 
sigmoidal curve with the Hill slope constrained to equal 1. In case of inhibition experiments with antagonists 
an equivalent analysis was followed to fit an inverse sigmoidal curve. To perform the statistical analysis of curve 
parameters, data from multiple experiments were fitted independently and resulting curve fit values were ana-
lysed with indicated tests. For radioligand binding data, saturation binding curves were generated by fitting the 
specific binding, which was obtained by subtracting non-specific from total binding, to a one site specific binding 
model that allows calculation of Kd values for the radioligand at wild type and mutant receptors. To determine 
affinity of unlabelled ligands, data obtained in displacement assays were fit to an inverse three parameter sig-
moidal curve constrained by radioligand affinity and concentration to allow for Ki calculation. To quantify the 
signaling bias that mutations of hFFA2 show compared to the wild type receptor, bias factor β was calculated by 
determining the logarithm of the ratio of relative intrinsic activities for a ligand at two different assays43. This 
approach requires only EC50 and Emax values of ligands in pathway 1 (cAMP or [35S]GTPγS assay) and 2 (TGFα 
shedding assay) at wild type and mutant receptors. Typically in such calculations a ligand of interest is assessed 
in comparison to a reference agonist that shows no bias between pathways 1 and 2, but in this case the response 
of agonist at wild type receptor serves as the reference to calculate the bias induced by respective mutations using 
the following equation.
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Data availability. The datasets generated and analysed during the current study are available from the cor-
responding author on reasonable request.
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